Sharenet Sites 
Sharenet Sites
Board and Committee Changes
British American Tobacco p.l.c.
Incorporated in England and Wales
(Registration number: 03407696)
Short name: BATS
Share code: BTI
ISIN number: GB0002875804
British American Tobacco p.l.c. (the "Company")
British American Tobacco p.l.c.
10 February 2025
Board and Committee Changes
Uta Kemmerich-Keil will join the Board of British American Tobacco p.l.c. (BAT) as an independent
Non-Executive Director with effect from 17 February 2025 and will be appointed as a member of the
Audit and Nominations Committees.
Uta previously held the role of Chief Executive Officer, Personal Healthcare International at P&G from
2018 to 2020, and prior to that spent 19 years at Merck Group where she held several roles including
Chief Executive Officer, Consumer Health Division, Chief Executive Officer, Allegropharma and Global
Business Unit Head, Allergy as well as Head of Corporate M&A, Treasury and Finance. Prior to joining
Merck Group, Uta was a Senior Financial Auditor at Hoechst AG. Uta currently serves as a member
of the Supervisory Board and Chair of the Audit Committee at Beiersdorf.
Commenting on the appointment, Luc Jobin, Chair of the Board, said: "I am pleased to welcome Uta
Kemmerich-Keil to our Board. Her strong general management background in regulated industries,
combined with her experience in consumer, digital and strategic transformation will be beneficial as
BAT continues on its ambition to build a Smokeless World".
BAT also announces that it has received notice from Murray S. Kessler, Non-Executive Director of the
Company, that he will step down from the Board with effect from 17 February 2025 to focus on his
recent appointment as Chief Executive Officer of Wellington International LLC.
Commenting on Murray's departure, Luc Jobin, said: "I would like to thank Murray for his contribution
during his tenure and his valuable insights to the Board. We wish him well in this new endeavour."
In light of the above changes, a review of the Company's Board Committees membership has been
undertaken. Karen Guerra, a Non-Executive Director of the Company, will join the Remuneration
Committee and step down from the Audit Committee with effect from 10 February 2025.
The Company's Audit Committee and Remuneration Committee membership as at 17 February 2025
is set out below:
Audit Committee Remuneration Committee
Darrell Thomas (Committee Chair) Kandy Anand (Committee Chair)
Holly Keller Koeppel Karen Guerra
Uta Kemmerich-Keil Serpil Timuray
Véronique Laury
Enquiries:
Media Centre
+44 (0) 20 7845 2888 (24 hours) | @BATplc
Investor Relations
Victoria Buxton: +44 (0)20 7845 2012 | IR_team@bat.com
Additional information
1. This announcement is made in compliance with the Company's obligations under UKLR 6.4.6.
2. In accordance with the Listing Rules, Uta Kemmerich-Keil is Board member of Beiersdorf AG and
Karo Healthcare AB (formerly listed as Karo Pharma AB). She was previously a Board member of
Biotest AG, Affimed N.V.. There are no additional matters that would require disclosure under UKLR
6.4.8 in respect of this appointment.
Sponsor: Merrill Lynch South Africa (Pty) Ltd t/a BofA Securities
Date: 10-02-2025 01:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
